Longitudinal analysis of lung cancer using tissue and blood samples.
Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics to Explore Biomarkers and Therapeutic Mechanisms.
This study is trying to see if changes in blood and tissue samples from lung cancer patients can help doctors tell the difference between harmless and harmful lung nodules and improve treatment plans.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2500 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University Academic / other |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06843707 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a longitudinal cohort of lung cancer patients by analyzing tissue and peripheral blood samples for metabolomics. It will focus on key treatment time points, including initial screening for lung nodules, postoperative evaluations, and therapeutic monitoring. The goal is to identify metabolic alterations that could serve as biomarkers for distinguishing between benign and malignant lung nodules, predicting treatment efficacy, and assessing long-term prognosis. By uncovering the underlying metabolic mechanisms, the study seeks to enhance personalized management of lung cancer.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with lung nodules confirmed by CT examination and good preoperative pulmonary function.
Not a fit: Patients with severe respiratory disorders or significant imaging artefacts in CT scans may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and prognostic tools for lung cancer patients.
How similar studies have performed: Other studies utilizing metabolomics in cancer research have shown promise, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signing of the informed consent form; 2. Male or female, aged 18-75 years; 3. Patients with lung nodules confirmed by CT examination; 4. Good preoperative pulmonary function cooperation and complete reporting; 5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging; 6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month. Exclusion Criteria: 1. Poor preoperative pulmonary function cooperation or missing reports; 2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission; 3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month; 4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.); 5. Coexisting with other severe functional impairments; 6. Patients with obstructive lesions such as airway or esophageal stenosis; (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Where this trial is running
Guangzhou, Guangdong
- the First Affiliated of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Jianxing He, Professer
- Email: drjiaxing.he@gmail.com
- Phone: 86-20-83337792
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.